From the Chief Medical Officer

• PL/CMO/2001/3 Diabetes - Imminent Phase Out Of Insulin Products By Lilly
• PL/CMO/2001/2 Instalment Prescribing Of Buprenorphine For The Treatment Of Drug Addiction
• PL/CMO/2001/1 Current Vaccine And Immunisation Issues
• PL/CMO/2000/3 Influenza Immunisation
• PL/CMO/2000/2 Good Practice in Continence Services
• PL/CMO/2000/1 Introduction of the Sure Start Maternity Grant
• PL/CMO/99/05 Current vaccine issues: action update.
• PL/CMO/99/04 Start Of The New Meningococcal C Conjugate Vaccine Immunisation Programme
• PL/CMO/99/03 Public Information Campaign On Antibotics Resistance To Be Launched In October
• PL/CMO/99/02 Introduction of Immunisation Against Group C Meningococcal Infection
• PL/CMO(99)1 Meningococcal Infection
• PL/CMO(98)6 Antimicrobial Resistance
• PL/CMO(98)5 Carbon Monoxide: the Forgotten Killer
• PL/CMO(98)4 Influenza Immunisation: Extension of current policy to include all those aged 75 years and over
• PL/CMO(98)3 Vitamin K for Newborn Babies
• PL/CMO(98)2 Measles, Measles Mumps Rubella (MMR) Vaccine, Crohn's disease and Autism
• PL/CMO(98)1 Clinical Examination of the Breast
• PL/CMO(97)3 Avian (H5N1) Influenza in Hong Kong
• PL/CMO(97)2 Urgent Communications
• PL/CMO(97)1 Meningococcal Infection: Meningitis & Septicaemia
• PL/CMO(96)5 New Variant of Creutzfeldt-Jakob Disease (CJD)